Literature DB >> 11866997

Post-transplant HHV-6 Diseases.

Giuseppe Gentile1.   

Abstract

Human herpesvirus 6 (HHV-6) infection is common in the general population. Primary infection occurs mainly in childhood, after which the virus establishes latency in the host and can be reactivated in immunocompromised individuals such as recipients of a solid organ or bone marrow transplant (BMT). HHV-6 infection occurs in 38--60% of BMT recipients and in 14--82% of solid organ recipients, usually 2--4 weeks post-transplantation. Two HHV-6 variants are recognized (HHV-6A and HHV-6B) and transplant patients are infected almost exclusively with variant B. Following BMT, the clinical diseases most commonly associated with HHV-6 infection are bone marrow suppression, interstitial pneumonitis, encephalitis and graft versus host disease. It has also been suggested that HHV-6 infection may be associated with fever and bone marrow suppression following liver transplantation and may contribute to rejection episodes after kidney transplantation. Infection with HHV-6 induces marked immunodepression, and an association both with cytomegalovirus disease and with fungal infection in transplant recipients has been reported. A direct causal relationship between HHV-6 infection and disease following transplantation, however, has yet to be proven conclusively.

Entities:  

Year:  2000        PMID: 11866997

Source DB:  PubMed          Journal:  Herpes        ISSN: 0969-7667


  4 in total

1.  Detection of HHV-6B in post-mortem central nervous system tissue of a post-bone marrow transplant recipient: a multi-virus array analysis.

Authors:  Karen Yao; Nahid Akyani; Donatella Donati; Naomi Sengamalay; Julie Fotheringham; Elodie Ghedin; Michael Bishop; John Barrett; Fatah Kashanchi; Steven Jacobson
Journal:  J Clin Virol       Date:  2006-12       Impact factor: 3.168

2.  Dominance of variant A in human herpesvirus 6 viraemia after renal transplantation.

Authors:  Eszter Csoma; Beáta Mészáros; Tamás Gáll; László Asztalos; József Kónya; Lajos Gergely
Journal:  Virol J       Date:  2011-08-15       Impact factor: 4.099

3.  Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.

Authors:  Karen Yao; Susan Gagnon; Nahid Akhyani; Elizabeth Williams; Julie Fotheringham; Elliot Frohman; Olaf Stuve; Nancy Monson; Michael K Racke; Steven Jacobson
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

4.  HHV-6 infection in a pediatric kidney transplant patient.

Authors:  Foteini Koukourgianni; Valérie Pichault; Aurélia Liutkus; Yves Gillet; Bruno Ranchin; Guillaume Mestrallet; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2009-07-07       Impact factor: 3.651

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.